NAD+ and sirtuins: the cofactor mechanism, end to end.

The NAD+ sirtuin mechanism is real cellular biology. The IV NAD+ infusion clinics built on it are mostly speculation. We need to separate the two.

This article is for researchers who want the actual biology, not the “longevity molecule” marketing shorthand. We’ll cover the electron-carrier role, the sirtuin substrate biology, the consumption pathways through PARP1 and CD38, the age decline hypothesis, the oral NMN/NR human trials, and the honest framing of where IV NAD+ does and doesn’t fit.

NAD+ as electron carrier: the energy story

NAD+’s first and most fundamental role is shuttling electrons during energy production. Glycolysis, the TCA cycle, oxidative phosphorylation. The trio of pathways cells use to convert glucose to ATP.

NAD+ picks up electrons from food molecules and carries them to the electron transport chain, where they ultimately power ATP synthesis. After dropping its electrons, NAD+ is regenerated and goes back for more. The NAD+/NADH ratio is one of the most-watched indicators of a cell’s energy state.

When NAD+ is plentiful, energy production runs forward. When it’s depleted (oxidative damage, metabolic stress), the pathways stall. Cells also use the ratio as a signal: they sense their NAD+ status and adjust gene expression accordingly.

This part of NAD+ biology is undisputed. Every cell-biology textbook since the 1950s covers it. The twist of the last two decades: NAD+ does more than carry electrons. Three other enzyme families consume it directly, breaking it apart instead of regenerating it.

NAD+

Dinucleotide Oxidized form Cellular cofactor

The same reference compound cited across the sirtuin, PARP, and CD38 mechanism literature in this article. Lab-verified identity and purity for in-vitro investigations of cellular energy metabolism and redox biology.

View NAD+

Sirtuins: NAD+ as gene-regulation fuel

Mammalian cells express seven sirtuins (SIRT1 through SIRT7). They are enzymes that strip acetyl groups (and other chemical tags) off proteins. Each deacetylation reaction consumes one NAD+ as a substrate.

That is the second role of NAD+. Not just an electron carrier. A consumed substrate that links cellular energy state to gene expression.

SIRT1 is the workhorse. It deacetylates the tumor-suppressor p53, the longevity-related FOXO transcription factors, the inflammation regulator NF-kB, and PGC-1-alpha (the master regulator of mitochondrial biogenesis). Sirtuins thus read the cell’s NAD+ status and regulate gene expression accordingly. When NAD+ is high, sirtuins are active. When NAD+ drops, sirtuin activity drops with it.

This is why NAD+ has been studied in the context of aging biology. The proposed chain runs: nutritional and metabolic stress state → cellular NAD+ levels → sirtuin activity → protein deacetylation → gene expression changes → cellular phenotype. Evidence from model-organism studies supports the general architecture of this pathway.

PARP1 and CD38: the NAD+ consumers

Two other enzyme families burn through NAD+, and they’re the reason NAD+ falls with age.

PARP1 is a DNA-repair enzyme. It attaches sugar chains to proteins at damaged DNA sites, marking them for repair. Each chain costs NAD+. In aging tissues, accumulated DNA damage keeps PARP1 chronically active, and the available NAD+ pool is correspondingly reduced for sirtuin activity.

CD38 is the bigger problem. It’s an enzyme on immune-cell surfaces that just degrades NAD+ to make calcium-signaling molecules. CD38 levels rise substantially with age, one of the most reproducible findings in this field. It’s now thought to be the main driver of age-related NAD+ decline. Researchers literally call it “the NAD+ thief.” Small-molecule CD38 inhibitors are an active drug-development area for this reason.

The picture: synthesis from precursors versus consumption by sirtuins, PARPs, and CD38. With age, CD38 in particular ramps up. Net result: tissue NAD+ falls. This is the “NAD World” hypothesis from the Imai and Sinclair labs.

The translation problem: from cellular biology to IV NAD+

Here’s where the honest framing matters. The cellular biology is settled. The age-related tissue decline is reproducible. The chain from NAD+ to sirtuin activity to gene expression is real. None of that proves IV NAD+ infusion delivers the predicted benefits.

The pharmacokinetic problem is as follows. NAD+ is a charged molecule that is rapidly degraded in plasma. Cellular uptake of intact NAD+ via the slc12a8 transporter remains contested in the literature. What likely reaches cells from an IV infusion is not intact NAD+ but its breakdown products (nicotinamide, ADP-ribose) — the same precursors that oral nicotinamide supplementation provides at a fraction of the cost (approximately 100-fold lower).

The clinical evidence backs the skeptical reading. A PubMed search for IV NAD+ RCTs in aging, addiction recovery, or energy enhancement returns almost nothing. The clinic claims have run ahead of the trial data by years.

Where the human RCT evidence actually lives: oral NMN and NR

The legitimate human RCT data is not on IV NAD+ but on oral precursors. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) both convert to NAD+ intracellularly via the salvage pathway. Both have generated controlled human trial data from 2020 onward.

The 2023 Yi trial randomised 80 middle-aged adults to placebo or 300, 600, or 900 mg NMN daily for 60 days. Blood NAD+ rose in all NMN groups. Six-minute walking distance improved. Health survey scores improved. The 2022 Igarashi trial of 250 mg/day NMN in older men showed higher blood NAD+ plus modest gait-speed and grip-strength gains. The 2024 Morifuji trial of 250 mg/day in 60 older adults showed faster walking and better sleep.

The pattern across trials: oral NMN at 250–900 mg/day reproducibly elevated blood NAD+ and was well tolerated. Modest functional improvements were reported — including incremental gains in walking speed, grip strength, and sleep scores. These effects were statistically significant but small in absolute magnitude, contrasting with broader claims in consumer-facing marketing.

What this means for IV NAD+ specifically

The IV NAD+ clinic claim is that direct injection delivers something oral precursors can’t. Faster, larger, more sustained, or some unique effect of intact NAD+. None of these claims has RCT support.

The methylation concern

One legitimate technical worry about high-dose NAD+ precursors: methyl-donor depletion.

Nicotinamide gets cleared by an enzyme called NNMT, which slaps a methyl group on it. The methyl group comes from S-adenosylmethionine (SAMe), the cell’s universal methyl donor. High flux through the nicotinamide pathway theoretically drains SAMe and could affect other methylation reactions including epigenetic regulation.

Whether this is clinically relevant at oral NMN/NR doses studied in RCTs has not been well characterised. Some research protocols have co-administered methyl-donor compounds (TMG, methylfolate) on this theoretical basis. This co-administration rationale is not RCT-validated. The related compound 5-Amino-1MQ, an NNMT inhibitor, is under investigation for related metabolic reasons — a mechanistically distinct approach to the same pathway.

Summary: what the evidence supports

NAD+ biology is real and important. The “NAD+ boosting” research program has produced controlled human trial data, though exclusively for oral precursors. The cellular mechanism story (sirtuin activation, mitochondrial biogenesis, DNA repair) is consistent across model systems. Human translation has shown modest effects at best. IV NAD+ clinic claims sit well beyond what the oral RCT evidence base supports.

NAD+

500 mg ≥99% pure Lyophilized

β-Nicotinamide adenine dinucleotide, oxidized form — the reference cofactor for in-vitro investigations into cellular energy metabolism, redox balance, sirtuin activity, and DNA repair pathways. COA available with each lot.

Learn more

Interpreting the NAD+ literature

The cellular biology — electron carrier, sirtuin substrate, PARP/CD38 consumption — is well-established textbook biochemistry.

The Imai/Sinclair NAD-decline hypothesis represents a coherent framework that has driven a productive research program. Its predictions regarding human anti-aging benefits remain only partially tested in controlled trials.

The oral NMN/NR RCT literature provides the most direct human evidence: modest, reproducible effects on physical function in study participants.

IV NAD+ clinic claims have run ahead of the controlled-trial evidence base, with an unresolved pharmacokinetic question about whether intact NAD+ reaches cells at therapeutic concentrations.